XML 95 R66.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborations - Additional Information (Details)
¥ in Millions
1 Months Ended 12 Months Ended
May 26, 2020
USD ($)
Jan. 01, 2019
USD ($)
Jan. 01, 2019
JPY (¥)
Jun. 30, 2020
USD ($)
May 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Jun. 23, 2020
shares
Dec. 31, 2019
USD ($)
Jan. 01, 2019
JPY (¥)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Proceeds from issuance of warrant           $ 15,000,000      
Common Shares                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Shares issued upon exercise of warrants outstanding | shares             750,000    
Bristol-Myers Squibb Company                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Non-refundable upfront payment received           50,000,000      
Affiliate of Bristol Myers Squibb                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Proceeds from issuance of warrant $ 15,000,000       $ 15,000,000        
Affiliate of Bristol Myers Squibb | Common Shares                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Shares issued upon exercise of warrants outstanding | shares             750,000    
Collaboration and License Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Non-refundable upfront payment received   $ 8,100,000       8,100,000   $ 8,100,000 ¥ 900
Initial nonrefundable upfront fee payment received   1,000,000 ¥ 110            
Deferred revenue, additions   7,300,000 750            
Collaboration and License Agreement | Bristol-Myers Squibb Company                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Non-refundable upfront payment received         $ 50,000,000        
Initial nonrefundable upfront fee payment received       $ 50,000,000          
Collaboration term expiration period         42 months        
Deferred revenue recognized           100,000      
Deferred revenue           49,900,000      
Deferred revenue, current           2,100,000      
Deferred revenue, noncurrent           $ 47,800,000      
Collaboration and License Agreement | Bristol-Myers Squibb Company | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Milestone payments entitled to be received         $ 301,000,000        
Research, Development and Regulatory Milestones | Collaboration and License Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Initial nonrefundable upfront fee payment received   7,100,000 ¥ 790            
Research, Development and Regulatory Milestones | Collaboration and License Agreement | Bristol-Myers Squibb Company | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Milestone payments entitled to be received         176,000,000        
Commercial Milestones | Collaboration and License Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Milestone payments entitled to be received   $ 166,700,000             ¥ 17,210
Commercial Milestones | Collaboration and License Agreement | Bristol-Myers Squibb Company | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Milestone payments entitled to be received         $ 125,000,000